ClinicalTrials.gg
RecruitingNCT07060807Updated Nov 3, 2026

A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

A Phase 3 interventional study of Patritumab deruxtecan and Paclitaxel in Breast Neoplasms, sponsored by Merck Sharp & Dohme LLC. Recruiting at 206 sites in 26 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 3 months later.
Updated Nov 3, 2026Site recruiting status changedEligibility revised+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,000
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing patritumab deruxtecan in Breast Neoplasms — 7 open to participants now, 9 under way, 1 of them phase 3. patritumab deruxtecan · Breast Neoplasms.

Planned enrollment
Largest of 12
1,000 · median 167
Started
2025
with 2 others
Phase 3
Only one
of the 12
Registered
11th of 12
by date
Lead sponsor
3 of 12
Merck Sharp & Dohme LLC

Among the 12 studies testing patritumab deruxtecan in Breast Neoplasms, this one has the largest planned enrollment, is one of 3 that started in 2025, is the only one in phase 3, and was the 11th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

7 of the 12 studies testing patritumab deruxtecan in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About patritumab deruxtecan

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing patritumab deruxtecan in Breast Neoplasms, or all of them as a file.
02

Study summary

Researchers are looking for other ways to treat breast cancer (BC) that is hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) and either unresectable locally advanced or metastatic.

  • HR positive (HR+) means the cancer cells have proteins that attach to estrogen or progesterone (hormones) which help the cancer to grow and spread
  • HER2 negative (HER2-) means the cancer cells have a low amount of a protein called HER2
  • Unresectable locally advanced means the cancer cannot be completely removed by surgery and has spread into nearby tissue or muscles
  • Metastatic means the cancer has spread to other parts of the body

Treatment for this type of breast cancer usually includes endocrine therapy (ET) and sometimes a second treatment. The main goal of this study is to learn if people who receive patritumab deruxtecan (also known as HER3-DXd and MK-1022) live longer overall or without the cancer growing/spreading, compared to people who receive chemotherapy or a different drug called trastuzumab deruxtecan.

03

Conditions studied

  • Breast Neoplasms

Browse trials for

04

Who can participate

The criteria were revised on the registry on Sep 28, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The main inclusion criteria include but are not limited to the following:

  • Has a diagnosis of hormone receptor positive (HR+)/human epidermal growth factor receptor 2 ()- invasive breast carcinoma that is either locally advanced disease not amenable to resection with curative intent (herein called unresectable) or disease not treatable with curative intent
  • Has centrally-confirmed HR+ and HER2- results and human epidermal growth factor receptor 3 (HER3) evaluable results from a obtained from a distant metastatic site or a locally advanced lesion on or after the time of diagnosis of locally advanced unresectable or metastatic breast cancer. A new biopsy obtained after progression of the most recent is preferred
  • Must have had progression or recurrence on prior cyclin-dependent kinase (CDK)4/6 inhibitor + endocrine therapy (ET) with one of the following:

    • Radiographic disease progression, as assessed by the investigator, on CDK4/6 inhibitor + ET as 1L for treatment of unresectable locally advanced or metastatic HR+/HER2- breast cancer. CDK4/6 inhibitor + ET must be the only line of therapy received in the advanced setting, or
    • Disease recurrence, either radiographic and/or confirmed histologically via biopsy as assessed by the investigator, while on adjuvant ET in combination with a CDK4/6 inhibitor OR within 24 months from the date of last dose of adjuvant CDK4/6 inhibitor
  • Has per 1.1 as assessed by the local site investigator/radiology
  • (HIV)-infected participants must have well controlled HIV on antiretroviral therapy
  • Has an performance status of 0 or 1 assessed within 7 days before randomization

Exclusion criteria

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following:

  • Has breast cancer amenable to treatment with curative intent
  • Is eligible to receive additional endocrine-based treatment in the advanced setting as determined by the investigator
  • Has a known germline breast cancer gene (BRCA) mutation (deleterious or suspected deleterious) where poly (ADP-ribose) polymerase (PARP) inhibitor(s) is a potential treatment option
  • Has current visceral crisis or is at risk for impending visceral crisis that has or may cause imminent organ compromise and/or other life-threatening complications
  • Has any of the following: a pulse oximeter reading \<92% at rest, or requires intermittent supplemental oxygen, or requires chronic supplemental oxygen
  • Has uncontrolled, significant cardiovascular disease or cerebrovascular disease
  • Has ≥Grade 2 peripheral neuropathy.
  • Has corneal disease
  • Has received prior chemotherapy for unresectable locally advanced or breast cancer
  • Has received prior treatment with an anti-HER3 antibody and/or antibody-drug conjugate that consists of a topoisomerase I inhibitor (eg, T-DXd) or any other topoisomerase I inhibitor therapy
  • Has received prior systemic anticancer therapy within 4 weeks (or 5 half-lives, whichever is shorter) before randomization; participants previously treated with ET plus a CDK4/6 inhibitor may participate as long as at least 2 weeks have elapsed since the last dose of therapy was administered
  • Has received prior radiotherapy for non-central nervous system disease, or required for radiation-related toxicities, within 14 days of the first dose of study intervention
  • Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy
  • Has known additional that is progressing or has required active treatment within the past 3 years
  • Has history of (noninfectious) interstitial lung disease (ILD) or pneumonitis irrespective of steroid use, or has current ILD or suspected ILD, or ILD that cannot be ruled out by imaging at Screening
  • Has severe (≥Grade 3) to HER3-DXd and/or any of its
  • Has severe hypersensitivity (≥Grade 3) to all the available TPC and/or any of their excipients
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,000 participants (estimated)

Study arms

  • Experimental
    Patritumab Deruxtecan

    Participants receive patritumab deruxtecan via intravenous (IV) infusion every 3 weeks (Q3W) for approximately 13 months.

    Biological: Patritumab deruxtecan · Drug: Rescue Medication

  • Active comparator
    Treatment of Physician's Choice

    Participants receive treatment of physician's choice (TPC) for up to 13 months. The TPC may be any of the following options: Paclitaxel (80 mg/m\^2) on Days 1, 8, 15, and 22 of each 4-week cycle; Paclitaxel (90 mg/m\^2) on Days 1, 8, and 15 of each 4-week cycle; Nab-paclitaxel (100 mg/m\^2) on Days 1, 8, and 15 of each 4-week cycle; Capecitabine (1000 mg/m\^2) bid on Days 1 to 14 of each 3-week cycle; Pegylated liposomal doxorubicin (50 mg/m\^2) on Day 1 of each 4-week cycle; or trastuzumab deruxtecan (T-DXd) (5.4 mg/kg) Q3W.

    Drug: Paclitaxel · Drug: Nab-paclitaxel · Drug: Capecitabine · Drug: Pegylated liposomal doxorubicin · Biological: Trastuzumab deruxtecan

Interventions

  • Administered via intravenous (IV) infusion

    Also known as: MK-1022, HER3-DXd, U3-1402

  • Administered via IV infusion

    Also known as: TAXOL®, ONXAL®

  • Administered via IV infusion

    Also known as: Abraxane®

  • Administered via oral tablets

    Also known as: XELODA®

  • Administered via IV infusion

    Also known as: Doxil®

  • Administered via IV infusion

    Also known as: T-DXd, Enhertu®

  • DrugRescue Medication

    Participants receive rescue medications according to each approved drug's product label. Recommended rescue medications include: 5-HT3 receptor antagonist, NK-1 receptor antagonist, and corticosteroids.

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS)

    PFS is defined as the time from first day of study intervention to the first documented progressive disease (PD) or death due to any cause, whichever occurs first as assessed by blinded independent central review (BICR). Per Response Evaluation Criteria In Solid Tumors (RECIST) 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. The appearance of one or more new lesions is also considered PD. PFS as assessed by BICR will be presented.

    Time frame: Up to approximately 45 months

  2. Overall Survival (OS)

    OS is the length of time from when the participant starts treatment until death from any cause.

    Time frame: Up to approximately 85 months

Secondary outcomes

  1. Objective Response Rate (ORR)

    ORR is defined as the percentage of participants with Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1 as assessed by BICR.

    Time frame: Up to approximately 85 months

  2. Duration of Response (DOR)

    For participants who demonstrate a confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR is defined as the time from first documented evidence of CR or PR until progressive disease (PD) or death. Per RECIST 1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD. DOR as assessed by BICR will be presented.

    Time frame: Up to approximately 85 months

  3. Change from Baseline in the European Organization for Research and Treatment of Cancer (EORTC)-Quality of Life Questionnaire-Core 30 (QLQ-C30) Global Health Status (Item 29) and Quality of Life (Item 30) Combined Score

    The EORTC QLQ-C30 is a cancer specific health-related quality-of life (QoL) questionnaire. Participant responses to the questions regarding Global Health Status (GHS; "How would you rate your overall health during the past week?") and Quality of Life (QoL; "How would you rate your overall quality of life during the past week?") are scored on a 7-point scale (1= Very poor to 7=Excellent). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A higher score indicates a better outcome. The change from baseline in GHS (EORTC QLQ-C30 Item 29) and QoL (EORTC QLQ-C30 Item 30) combined score (the standardized average of the raw scores) will be presented.

    Time frame: Baseline and up to approximately 85 months

  4. Change from Baseline in the EORTC-QLQ-C30 Physical Functioning (Items 1-5) Combined Score

    The EORTC QLQ-C30 is a cancer specific health-related quality-of-life questionnaire. Participant responses to 5 questions about their physical functioning (Items 1-5) are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. Higher scores indicate better physical functioning. The change from baseline in EORTC QLQ-C30 Physical Functioning (Items 1-5) combined score (the standardized average of the raw scores) will be presented.

    Time frame: Baseline and up to approximately 85 months

  5. Change from Baseline in the EORTC-QLQ-C30 Emotional Functioning (Items 1-5) Combined Score

    The EORTC QLQ-C30 is a cancer specific health-related quality-of-life questionnaire. Participant responses to 4 questions about their emotional functioning (Items 21-24) are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. Higher scores indicate better emotional functioning. The change from baseline in EORTC QLQ-C30 Emotional Functioning (Items 21-24) combined score (the standardized average of the raw scores) will be presented.

    Time frame: Baseline and up to approximately 85 months

  6. Change from Baseline in the EORTC-QLQ-C30 Pain (Items 9 and 19) Combined Score

    The EORTC QLQ-C30 is a cancer specific health-related quality-of-life questionnaire. Participant responses to 2 questions about their pain (Items 9 and 19) are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. Higher scores indicate greater pain. The change from baseline in EORTC QLQ-C30 Pain (Items 9 and 19) combined score (the standardized average of the raw scores) will be presented.

    Time frame: Baseline and up to approximately 85 months

  7. Time to First Deterioration (TTD) in the European Organization for Research and Treatment of Cancer (EORTC)-Quality of Life Questionnaire-Core 30 (QLQ-C30) Global Health Status (Item 29) and Quality of Life (Item 30) Combined Score

    The EORTC QLQ-C30 is a cancer specific health-related quality-of life (QoL) questionnaire. Participant responses to the questions regarding Global Health Status (GHS; "How would you rate your overall health during the past week?") and Quality of Life (QoL; "How would you rate your overall quality of life during the past week?") are scored on a 7-point scale (1= Very poor to 7=Excellent). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A higher score indicates a better outcome. The TTD from baseline in GHS (EORTC QLQ-C30 Item 29) and QoL (EORTC QLQ-C30 Item 30) combined score (the standardized average of the raw scores), defined as the time from baseline to the first onset of a 10 or more points deterioration from baseline, will be presented.

    Time frame: Baseline and up to approximately 85 months

  8. TTD in the EORTC-QLQ-C30 Physical Functioning (Items 1-5) Combined Score

    The EORTC QLQ-C30 is a cancer specific health-related quality-of-life questionnaire. Participant responses to 5 questions about their physical functioning (Items 1-5) are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. Higher scores indicate better physical functioning. The TTD from baseline in EORTC QLQ-C30 Physical Functioning (Items 1-5) combined score (the standardized average of the raw scores), defined as the time from baseline to the first onset of a 10 or more points deterioration from baseline, will be presented.

    Time frame: Baseline and up to approximately 85 months

  9. TTD in the EORTC-QLQ-C30 Emotional Functioning (Items 1-5) Combined Score

    The EORTC QLQ-C30 is a cancer specific health-related quality-of-life questionnaire. Participant responses to 4 questions about their emotional functioning (Items 21-24) are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. Higher scores indicate better emotional functioning. The TTD from baseline in EORTC QLQ-C30 Emotional Functioning (Items 21-24) combined score (the standardized average of the raw scores) defined as the time from baseline to the first onset of a 10 or more points deterioration from baseline, will be presented.

    Time frame: Baseline and up to approximately 85 months

  10. TTD in the EORTC-QLQ-C30 Pain (Items 9 and 19) Combined Score

    The EORTC QLQ-C30 is a cancer specific health-related quality-of-life questionnaire. Participant responses to 2 questions about their pain (Items 9 and 19) are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. Higher scores indicate greater pain. The TTD from baseline in EORTC QLQ-C30 Pain (Items 9 and 19) combined score (the standardized average of the raw scores), will be presented.

    Time frame: Baseline and up to approximately 85 months

  11. Number of Participants Who Experience One or More Adverse Event (AEs)

    An AE is any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE. The number of participants who experience an AE will be presented.

    Time frame: Up to approximately 85 months

  12. Number of Participants Who Discontinue Study Treatment Due to an AE

    An AE is any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE. The number of participants who discontinue study treatment due to an AE will be presented.

    Time frame: Up to approximately 85 months

07

Study locations

203 of 206 sites recruiting
  • Southern Cancer Center (SCC) ( Site 8000)
    Daphne, Alabama 36526, United States
    Recruiting
    • Study Coordinator · Contact251-607-5283
  • The University of Arizona Cancer Center - North Campus ( Site 0055)
    Tucson, Arizona 85719, United States
    Recruiting
    • Study Coordinator · Contact520-626-0191
  • Los Angeles Hematology Oncology Medical Group ( Site 0026)
    Los Angeles, California 90017, United States
    Recruiting
    • Study Coordinator · Contact626-627-6666
  • Hoag Memorial Hospital Presbyterian ( Site 0025)
    Newport Beach, California 92663, United States
    Recruiting
    • Study Coordinator · Contact949-764-5501
  • St. Marys Hospital and Regional Medical Center-SCL Health Cancer Centers of Colorado ( Site 0021)
    Grand Junction, Colorado 81501, United States
    Recruiting
    • Study Coordinator · Contact970-298-7638
  • Medical Oncology Hematology Consultants (MOHC) ( Site 8002)
    Newark, Delaware 19713, United States
    Recruiting
    • Study Coordinator · Contact302-366-1200
  • AdventHealth Medical Group Oncology and Hematology at Altamonte ( Site 0024)
    Altamonte Springs, Florida 32701, United States
    Recruiting
    • Study Coordinator · Contact407-834-5151
  • Comprehensive Hematology Oncology ( Site 0060)
    St. Petersburg, Florida 33709, United States
    Recruiting
    • Study Coordinator · Contact727-344-6569
  • Baptist Health Lexington ( Site 0050)
    Lexington, Kentucky 40503, United States
    Recruiting
    • Study Coordinator · Contact859-509-3044
  • Baptist Health Hamburg ( Site 0071)
    Lexington, Kentucky 40509, United States
    Recruiting
    • Study Coordinator · Contact859-639-7827
  • Cancer Care Specialists ( Site 9503)
    Reno, Nevada 89511, United States
    Recruiting
    • Study Coordinator · Contact775-329-0222x230
  • John Theurer Cancer Center at Hackensack University Medical Center ( Site 0001)
    Hackensack, New Jersey 07601, United States
    Recruiting
    • Study Coordinator · Contact551-996-5900
  • Rutgers Cancer Institute of New Jersey ( Site 0033)
    New Brunswick, New Jersey 08903, United States
    Recruiting
    • Study Coordinator · Contact732-235-2465
  • Presbyterian Kaseman Hospital ( Site 0072)
    Albuquerque, New Mexico 87110, United States
    Recruiting
    • Study Coordinator · Contact505-925-0405
  • University of New Mexico Comprehensive Cancer Center ( Site 0047)
    Albuquerque, New Mexico 87131, United States
    Recruiting
    • Study Coordinator · Contact505-272-4946
  • Presbyterian Rust Jorgensen Cancer ( Site 0073)
    Rio Rancho, New Mexico 87124, United States
    Recruiting
    • Study Coordinator · Contact505-253-7878
  • Queens Hospital Cancer Center ( Site 0011)
    Jamaica, New York 11432, United States
    Recruiting
    • Study Coordinator · Contact718-883-4133
  • Optum Medical Care, PC ( Site 0009)
    Westbury, New York 11590, United States
    Recruiting
    • Study Coordinator · Contact516-488-2918
  • Novant Health Cancer Institute ( Site 0019)
    Charlotte, North Carolina 28204, United States
    Recruiting
    • Study Coordinator · Contact980-302-6500
  • Novant Health Oncology Specialists ( Site 0074)
    Winston-Salem, North Carolina 27103, United States
    Recruiting
    • Study Coordinator · Contact336-277-8800
  • TriHealth Cancer Institute-Good Samaritan Hospital ( Site 0020)
    Cincinnati, Ohio 45220, United States
    Recruiting
    • Study Coordinator · Contact513-865-9460
  • University of Pittsburgh Medical Center Magee-Womens Hospital ( Site 0058)
    Pittsburgh, Pennsylvania 15213, United States
    Recruiting
    • Study Coordinator · Contact412-641-6500
  • Cancer Care Associates Of York ( Site 0063)
    York, Pennsylvania 17403, United States
    Recruiting
    • Study Coordinator · Contact717-741-9229
  • SCRI Oncology Partners ( Site 7000)
    Nashville, Tennessee 37203, United States
    Recruiting
    • Study Coordinator · Contact615-329-7274
  • Tennessee Oncology ( Site 0068)
    Nashville, Tennessee 37203, United States
    Recruiting
    • Study Coordinator · Contact615-320-5090
  • Texas Oncology - DFW ( Site 8003)
    Dallas, Texas 75246, United States
    Recruiting
    • Study Coordinator · Contact214-370-1794
  • JPS Health Network ( Site 0067)
    Fort Worth, Texas 76104, United States
    Recruiting
    • Study Coordinator · Contact817-702-8049
  • Texas Oncology - Gulf Coast ( Site 8006)
    Houston, Texas 77024, United States
    Recruiting
    • Study Coordinator · Contact713-467-1722
  • Oncology Consultants P.A. ( Site 0061)
    Houston, Texas 77030, United States
    Recruiting
    • Study Coordinator · Contact713-516-4968
  • Texas Oncology - Central/South Texas ( Site 8005)
    McAllen, Texas 78503, United States
    Recruiting
    • Study Coordinator · Contact956-687-5150
  • Mays Cancer Center ( Site 0049)
    San Antonio, Texas 78229, United States
    Recruiting
    • Study Coordinator · Contact210-450-3838
  • Virginia Oncology Associates (VOA) ( Site 8001)
    Norfolk, Virginia 23502, United States
    Recruiting
    • Study Coordinator · Contact757-368-5033
  • Shenandoah Oncology ( Site 8004)
    Winchester, Virginia 22601, United States
    Recruiting
    • Study Coordinator · Contact540-662-1108
  • Northwest Medical Specialties, PLLC ( Site 0062)
    Tacoma, Washington 98405, United States
    Recruiting
    • Study Coordinator · Contact253-841-4296
  • Circuit Clinical/SSM Health Dean Medical Group ( Site 0039)
    Madison, Wisconsin 53715, United States
    Recruiting
    • Study Coordinator · Contact608-355-2033
  • Hospital Aleman ( Site 0200)
    Ciudad Autonoma de Buenos Aires, Buenos Aires C1118AAT, Argentina
    Recruiting
    • Study Coordinator · Contact+541148277000X2306
  • Instituto de Investigaciones Clínicas Mar del Plata ( Site 0205)
    Mar del Plata, Buenos Aires B7600FZO, Argentina
    Recruiting
    • Study Coordinator · Contact+542234963224
  • Fundación Respirar ( Site 0201)
    Buenos Aires, Buenos Aires F.D. C1426AAL, Argentina
    Recruiting
    • Study Coordinator · Contact+541170781548
  • Centro Privado de RMI Rio Cuarto ( Site 0207)
    Río Cuarto, Córdoba Province X5800ALB, Argentina
    Recruiting
    • Study Coordinator · Contact+543584620273
  • Instituto de Oncología de Rosario ( Site 0208)
    Rosario, Santa Fe Province S2000KZE, Argentina
    Recruiting
    • Study Coordinator · Contact+543414218909
  • Instituto Alexander Fleming ( Site 0202)
    CABA, C1426DRB, Argentina
    Recruiting
    • Study Coordinator · Contact+541132218900
  • Hospital Italiano de Córdoba ( Site 0206)
    Córdoba, X5004BAL, Argentina
    Recruiting
    • Study Coordinator · Contact+543514106500
  • Blacktown Hospital-Blacktown Cancer and Haematology Centre - Medical Oncology ( Site 2300)
    Blacktown, New South Wales 2148, Australia
    Recruiting
    • Study Coordinator · Contact02 8670 5077
  • Chris O'Brien Lifehouse ( Site 2302)
    Camperdown, New South Wales 2050, Australia
    Recruiting
    • Study Coordinator · Contact+61 2 85140922
  • Monash Medical Centre ( Site 2301)
    Clayton, Victoria 3168, Australia
    Recruiting
    • Study Coordinator · Contact+61 3 85722941
  • The Alfred Hospital ( Site 2305)
    Melbourne, Victoria 3004, Australia
    Recruiting
    • Study Coordinator · Contact03 9076 2000
  • Sir Charles Gairdner Hospital ( Site 2304)
    Nedlands, Western Australia 6009, Australia
    Recruiting
    • Study Coordinator · Contact08 6457 3333
  • Hospital de Câncer de Recife ( Site 0302)
    Recife, Pernambuco 50040-000, Brazil
    Recruiting
    • Study Coordinator · Contact+558132178084
  • Liga Norte Riograndense Contra o Câncer ( Site 0301)
    Natal, Rio Grande do Norte 59062-000, Brazil
    Recruiting
    • Study Coordinator · Contact+558440095595
  • Hospital do Câncer Mãe de Deus ( Site 0300)
    Porto Alegre, Rio Grande do Sul 90470-340, Brazil
    Recruiting
    • Study Coordinator · Contact+555132344345
  • Instituto de Oncologia Saint Gallen ( Site 0308)
    Santa Cruz do Sul, Rio Grande do Sul 96830-180, Brazil
    Recruiting
    • Study Coordinator · Contact+555130568686
  • ANIMI - Unidade de Tratamento Oncologico ( Site 0306)
    Lages, Santa Catarina 88501-001, Brazil
    Recruiting
    • Study Coordinator · Contact+554933805220
  • Hospital Paulistano ( Site 0304)
    São Paulo, 01321-001, Brazil
    Recruiting
    • Study Coordinator · Contact+5511944716385
  • The Moncton Hospital ( Site 0101)
    Moncton, New Brunswick E1C 6Z8, Canada
    Recruiting
    • Study Coordinator · Contact5068575756
  • Sunnybrook Research Institute ( Site 0105)
    Toronto, Ontario M4N 3M5, Canada
    Recruiting
    • Study Coordinator · Contact416-480-5248
  • Princess Margaret Cancer Center ( Site 0116)
    Toronto, Ontario M5G 2M9, Canada
    Recruiting
    • Study Coordinator · Contact416-946-4501
  • Centre Hospitalier de l'Université de Montréal ( Site 0113)
    Montreal, Quebec H2X 3E4, Canada
    Recruiting
    • Study Coordinator · Contact5148908000
  • Saskatoon Cancer Centre ( Site 0106)
    Saskatoon, Saskatchewan S7N 4H4, Canada
    Recruiting
    • Study Coordinator · Contact306-655-2662
  • CIDO SpA ( Site 0408)
    Temuco, Araucania 4810218, Chile
    Recruiting
    • Study Coordinator · Contact56934016366
  • Fundación Arturo López Pérez ( Site 0400)
    Santiago, Region M. de Santiago 7500921, Chile
    Recruiting
    • Study Coordinator · Contact+56224205098
  • Oncovida ( Site 0402)
    Santiago, Region M. de Santiago 7500994, Chile
    Recruiting
    • Study Coordinator · Contact+56225992900
  • Centro de Oncología de Precisión ( Site 0410)
    Santiago, Region M. de Santiago 7560908, Chile
    Recruiting
    • Study Coordinator · Contact+56225189885
  • Clínica MEDS La Dehesa ( Site 0405)
    Santiago, Region M. de Santiago 7691236, Chile
    Recruiting
    • Study Coordinator · Contact+56224996400
  • Bradfordhill ( Site 0401)
    Santiago, Region M. de Santiago 8420383, Chile
    Recruiting
    • Study Coordinator · Contact+56229490970
  • Anhui Provincial Cancer Hospital ( Site 3140)
    Hefei, Anhui 230088, China
    Recruiting
    • Study Coordinator · Contact0551-65327666
  • Cancer Hospital Chinese Academy of Medical Sciences ( Site 3100)
    Beijing, Beijing Municipality 100021, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Peking University People's Hospital ( Site 3138)
    Beijing, Beijing Municipality 100044, China
    Recruiting
    • Study Coordinator · Contact010-88326666
  • The First Affiliated Hospital of Chongqing Medical University ( Site 3101)
    Chongqing, Chongqing Municipality 400016, China
    Recruiting
    • Study Coordinator · Contact02389011515
  • Chongqing Three Gorges Central Hospital's ( Site 3128)
    Wanzhou, Chongqing Municipality 404000, China
    Recruiting
    • Study Coordinator · Contact02358103238
  • The First Affiliated hospital of Xiamen University ( Site 3120)
    Fujian, Fujian 361003, China
    Recruiting
    • Study Coordinator · Contact0592-2137327
  • Sun Yat-Sen University Cancer Center ( Site 3102)
    Guangzhou, Guangdong 510060, China
    Recruiting
    • Study Coordinator · Contact020-87342479
  • Jiangmen Central Hospital ( Site 3132)
    Jiangmen, Guangdong 529000, China
    Recruiting
    • Study Coordinator · Contact0750-3989521
  • Guangxi Medical University Affiliated Tumor Hospital ( Site 3118)
    Nanning, Guangxi 530021, China
    Recruiting
    • Study Coordinator · Contact0771-5331955
  • Henan Cancer Hospital ( Site 3108)
    Zhengzhou, Henan 450008, China
    Recruiting
    • Study Coordinator · Contact0371-65588007
  • Xiangyang Central Hospital ( Site 3123)
    Xiangyang, Hubei 441106, China
    Recruiting
    • Study Coordinator · Contact+8607102810910
  • Hunan Cancer Hospital ( Site 3134)
    Changsha, Hunan 410013, China
    Recruiting
    • Study Coordinator · Contact0731-89762160
  • Jiangsu Cancer Hospital ( Site 3107)
    Nanjing, Jiangsu 210009, China
    Recruiting
    • Study Coordinator · Contact+8602583283415
  • Jiangsu Province Hospital ( Site 3105)
    Nanjing, Jiangsu 210029, China
    Recruiting
    • Study Coordinator · Contact02568308145
  • Nanchang People's Hospital ( Site 3124)
    Nanchang, Jiangxi 330008, China
    Recruiting
    • Study Coordinator · Contact0791-86728121
  • Jilin Cancer Hospital ( Site 3116)
    Changchun, Jilin 132000, China
    Recruiting
    • Study Coordinator · Contact0431-80596065
  • Xi'an International Medical Center Hospital ( Site 3122)
    Xi'an, Shaanxi 710100, China
    Recruiting
    • Study Coordinator · Contact02968302436
  • Affiliated Cancer Hospital of Shandong First Medical University ( Site 3115)
    Jinan, Shandong 250117, China
    Recruiting
    • Study Coordinator · Contact0531-67626073
  • Sichuan Cancer Hospital. ( Site 3110)
    Chengdu, Sichuan 610041, China
    Recruiting
    • Study Coordinator · Contact02885420509
  • West China Hospital of Sichuan University ( Site 3139)
    Chengdu, Sichuan 610041, China
    Recruiting
    • Study Coordinator · Contact028-85422114
  • Xinjiang Medical University Cancer Hospital - Urumqi ( Site 3112)
    Ürümqi, Xinjiang 830000, China
    Completed

    Not enrolling at this site — choose another above.

  • Sir Run Run Shaw Hospital ( Site 3117)
    Hangzhou, Zhejiang 310016, China
    Recruiting
    • Study Coordinator · Contact+8657186960497
  • Zhejiang Cancer Hospital ( Site 3109)
    Hangzhou, Zhejiang 310022, China
    Recruiting
    • Study Coordinator · Contact0571-88122072
  • Taizhou Hospital of Zhejiang Province ( Site 3137)
    Linhai, Zhejiang 317000, China
    Recruiting
    • Study Coordinator · Contact+86 0516 85120120
  • Promotora Médica Las Américas S.A. ( Site 0503)
    Medellín, Antioquia 050025, Colombia
    Recruiting
    • Study Coordinator · Contact+573043826133
  • FUNDACION CTIC CENTRO DE TRATAMIENTO E INVESTIGACION SOBRE CANCER LUIS CARLOS SARMIENTO ANGULO ( Site 0502)
    Bogotá, Bogota D.C. 110131, Colombia
    Recruiting
    • Study Coordinator · Contact(+57) 3183662238
  • Instituto Nacional De Cancerologia ( Site 0504)
    Bogotá, Bogota D.C. 111511, Colombia
    Recruiting
    • Study Coordinator · Contact+57 3004224753
  • Sociedad De Oncología y Hematología Del Cesar SAS ( Site 0501)
    Valledupar, Cesar Department 200001, Colombia
    Recruiting
    • Study Coordinator · Contact+5755602310
  • IMAT S.A.S ( Site 0500)
    Montería, Departamento de Córdoba 230002, Colombia
    Recruiting
    • Study Coordinator · Contact+57 300 2152346
  • CHRU de Brest ( Site 0904)
    Brest, Finistere 29200, France
    Recruiting
    • Study Coordinator · Contact+33298233987
  • CENTRE LEON BERARD ( Site 0900)
    Lyon, Rhone 69008, France
    Recruiting
    • Study Coordinator · Contact+33478782654
  • Centre de Lutte Contre le Cancer - Centre Henri Becquerel Normandie Rouen ( Site 0901)
    Rouen, Seine-Maritime 76038, France
    Recruiting
    • Study Coordinator · Contact+33232082220
  • Gustave Roussy ( Site 0903)
    Villejuif, Val-de-Marne 94800, France
    Recruiting
    • Study Coordinator · Contact+33142116162
  • Universitaetsklinikum Ulm-Frauenheilkunde und Geburtshilfe ( Site 1001)
    Ulm, Baden-Wurttemberg 89075, Germany
    Recruiting
    • Study Coordinator · Contact+4973150058523
  • Klinikum Lippe Detmold ( Site 1008)
    Detmold, North Rhine-Westphalia 32756, Germany
    Recruiting
    • Study Coordinator · Contact+49 5231 720
  • Klinikum Dortmund Klinikzentrum Mitte ( Site 1005)
    Dortmund, North Rhine-Westphalia 44137, Germany
    Recruiting
    • Study Coordinator · Contact+4923195320733

Showing the first 100 of 206 sites across 26 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

09

Timeline

6 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Jul 2033, 95 months after the start.

Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's planned 95 months is above that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 2, 2025
First posted
Jul 11, 2025
StartActual
Jul 21, 2025
Primary completionEst.
Jul 14, 2033
CompletionEst.
Jul 14, 2033
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
9 sites added, 2 sites removed. Xinjiang Medical University Cancer Hospital - Urumqi ( Site 3112) is now Completed
Show 9 added (2 Germany, 1 Hong Kong, 1 Israel, 1 Chile, 1 United States, 1 Greece, 1 United Kingdom, 1 Vietnam)
  • Queen Mary Hospital ( Site 3300) · Hong Kong, Hong Kong
  • Soroka Medical Center ( Site 1407) · Beersheba, Israel
  • Fundación Arturo López Pérez ( Site 0400) · Santiago, Chile
  • Klinikum Chemnitz gGmbH ( Site 1016) · Chemnitz, Germany
  • Cancer Care Specialists ( Site 9503) · Reno, United States
  • "ALEXANDRA" GENERAL HOSPITAL OF ATHENS - DEPARTMENT OF CLINICAL THERAPEUTICS ( Site 1106) · Athens, Greece
  • Guy s and St Thomas Hospital NHS Foundation Trust ( Site 2201) · London, United Kingdom
  • Ho Chi Minh City Oncology Hospital ( Site 3032) · Ho Chi Minh City, Vietnam
  • Universitaetsklinikum Ulm-Frauenheilkunde und Geburtshilfe ( Site 1001) · Ulm, Germany
Show 2 removed
  • Queen Mary Hospital ( Site 3300) · Pokfulam, Hong Kong
  • FALP ( Site 0400) · Santiago, Chile
across 6 updates, Sep 28, 2026 – Nov 3, 2026
Eligibility
1 inclusion criterion edited; 1 exclusion criterion edited
What changed in the criteria
Inclusion criteria
  • EditedHas centrally-confirmed HR+ and HER2- results and human epidermal growth factor receptor 3 (HER3) evaluable results from a biopsy obtained from a distant metastatic site or a locally advanced lesion on or after the time of diagnosis of locally advanced unresectable or metastatic breast cancer. A new biopsy obtained after progression of the most recent line of therapy (with certain exceptions)is preferred
Exclusion criteria
  • EditedHas history of (noninfectious) pneumonitis/interstitial lung disease (ILD) that required steroids, has currentor pneumonitis/interstitial lung disease irrespective of steroid use, or has current ILD or suspected ILD/pneumonitis, or ILD that cannot be ruled out by imaging at Screening
Sep 28, 2026
Interventions
Changed Liposomal doxorubicin→Pegylated liposomal doxorubicin. Added Drug: Rescue Medication
Sep 28, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Xinjiang Medical University Cancer Hospital - Urumqi ( Site 3112) · Ürümqi, ChinaContact removed •••9133
Nov 3, 2026
Show all 6 updates
  1. Nov 3, 2026
    1 site added. Xinjiang Medical University Cancer Hospital - Urumqi ( Site 3112) is now Completed
    Show site
    • Universitaetsklinikum Ulm-Frauenheilkunde und Geburtshilfe ( Site 1001) · Ulm, Germany
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Xinjiang Medical University Cancer Hospital - Urumqi ( Site 3112) · Ürümqi, ChinaContact removed •••9133
  2. Oct 23, 2026
    1 site added
    Show site
    • Ho Chi Minh City Oncology Hospital ( Site 3032) · Ho Chi Minh City, Vietnam
    + 1 other change: references
  3. Oct 19, 2026
    3 sites added
    Show 3 added (1 United States, 1 Greece, 1 United Kingdom)
    • Cancer Care Specialists ( Site 9503) · Reno, United States
    • "ALEXANDRA" GENERAL HOSPITAL OF ATHENS - DEPARTMENT OF CLINICAL THERAPEUTICS ( Site 1106) · Athens, Greece
    • Guy s and St Thomas Hospital NHS Foundation Trust ( Site 2201) · London, United Kingdom
  4. Oct 8, 2026
    1 site added
    Show site
    • Klinikum Chemnitz gGmbH ( Site 1016) · Chemnitz, Germany
  5. Oct 6, 2026
    1 site added, 1 site removed
    Show site
    • Fundación Arturo López Pérez ( Site 0400) · Santiago, Chile
    Show 1 removed
    • FALP ( Site 0400) · Santiago, Chile
    + 1 other change: verification date
  6. Sep 28, 2026
    2 sites added, 1 site removed
    Show 2 added (1 Hong Kong, 1 Israel)
    • Queen Mary Hospital ( Site 3300) · Hong Kong, Hong Kong
    • Soroka Medical Center ( Site 1407) · Beersheba, Israel
    Show 1 removed
    • Queen Mary Hospital ( Site 3300) · Pokfulam, Hong Kong
    Eligibility 1 inclusion criterion edited; 1 exclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • EditedHas centrally-confirmed HR+ and HER2- results and human epidermal growth factor receptor 3 (HER3) evaluable results from a biopsy obtained from a distant metastatic site or a locally advanced lesion on or after the time of diagnosis of locally advanced unresectable or metastatic breast cancer. A new biopsy obtained after progression of the most recent line of therapy (with certain exceptions)is preferred
    Exclusion criteria
    • EditedHas history of (noninfectious) pneumonitis/interstitial lung disease (ILD) that required steroids, has currentor pneumonitis/interstitial lung disease irrespective of steroid use, or has current ILD or suspected ILD/pneumonitis, or ILD that cannot be ruled out by imaging at Screening
    Interventions Changed Liposomal doxorubicin→Pegylated liposomal doxorubicin. Added Drug: Rescue Medication
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07060807
Collaborators
Daiichi Sankyo
Responsible party
Sponsor
First posted
Jul 11, 2025
Start date
Jul 21, 2025
Primary completion
Jul 14, 2033 (estimated)
Completion
Jul 14, 2033 (estimated)
Last update
Nov 3, 2026

Study contacts

Toll Free Number
Contact
Trialsites@msd.com
1-888-577-8839
Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Patritumab deruxtecan

Start the discussion